ARCHIVES

BCDDP Follow Up To Cost $1.6 Million annually For Five Years Okayed; Limited To 59,000 Women

This article is from The Cancer Letter archive.

Vol. 04 No. 44 | November 3, 1978

Download PDF Visit The Full Archive

Related Articles

IOM Says “Immediate Steps” Needed To Avert “Crisis” In Cancer Centers Program Funding

April 28, 1989

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

January 14, 2005

DCT To Examine Groups’ Studies, Directions, Role in 2000 A.D. Goal

June 8, 1984

In Brief: Adjuvant Chemotherapy Standard Practice For Breast Cancer At Milan, Bonadonna Says

May 7, 1976

Zwelling Moves to Legacy Community Health

July 19, 2013

NCAB Needs Focus, Strong Membership To Better Advise NCI, Chairman Rimer Says

September 22, 1995